Advertisement

Management of Pregnancy in HIV-Infected Women and Prevention of Mother-to-Child Transmission

  • Arlene D. Bardeguez
Chapter

Abstract

Although the HIV/AIDS cases worldwide continue to increase, the USA and other developed countries have witnessed an enhanced survival of chronically infected individuals, a decrease in mother-to-child transmission (MTCT) of HIV-1 infection, and a growing number of medical and behavioral interventions that can decrease new infections. In spite of the amazing progress over the last two decades we still face challenges in empowering our patients to know their HIV diagnosis and that of their partner prior to conception, in the management of HIV-infected pregnant women based on their age, chronic illness, and behavioral risk patterns. We also face the dilemma of how to support discordant or concordant couples who desire to conceive in a financially challenged environment as the demographic profile of this population evolves and long-term survival is feasible.

Keywords

Operative Delivery Unborn Child External Cephalic Version Neural Tube Defect Pediatric AIDS Clinical Trial Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    CDC. HIV/AIDS surveillance report, 2006. Vol 18. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2008. Available at http//www.cdc.gov/hiv/topics/surveillance/resources/reports.Google Scholar
  2. 2.
    UNAIDS. 2006 report on the global AIDS epidemic. A UNAIDS 10th anniversary special edition.Google Scholar
  3. 3.
    Centers for Disease Control and Prevention. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health Care Settings. MMWR 2006:55 (No RR-14):1–16.Google Scholar
  4. 4.
    Jamieson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol. 2007;197(3 Suppl):S26–32.PubMedGoogle Scholar
  5. 5.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173–80.PubMedGoogle Scholar
  6. 6.
    Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmne immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatrics AIDS Clinical Trials Group Protocol 185. J Infect Dis. 1999;179:567–75.PubMedGoogle Scholar
  7. 7.
    Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335(22):1621–9.PubMedGoogle Scholar
  8. 8.
    Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385–93.PubMedGoogle Scholar
  9. 9.
    Garcia PM. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341(6):394–402PubMedGoogle Scholar
  10. 10.
    Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–1414.PubMedGoogle Scholar
  11. 11.
    Fiscus SA, Adimora AA, Schoenback VJ, et al. Trends in human immunodeficiency virus(HIV) counseling, testing and antiretroviral treatment of HIV infected women and perinatal transmission in North Carolina. J Infect. 1999;180:99–105.Google Scholar
  12. 12.
    Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. J Pediatr. 1997;131:857–62.PubMedGoogle Scholar
  13. 13.
    Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. JAMA. 2002;288(2):189–98.PubMedGoogle Scholar
  14. 14.
    Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484–94.PubMedGoogle Scholar
  15. 15.
    The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet. 1999;353(9158):1035–9.Google Scholar
  16. 16.
    The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 – a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340(13):977–87.Google Scholar
  17. 17.
    ACOG Committee Opinion. Scheduled Cesarean Delivery and the Prevention of Vertical Transmission of HIV Infection. May 2000;234(219).Google Scholar
  18. 18.
    Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. July 8, 2008. AIDSinfo Web site (http://AIDSinfo.nih.gov.)
  19. 19.
    Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2001;26:236–45.PubMedGoogle Scholar
  20. 20.
    Marcollet A, Goffinet F, Firtion G, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol. 2002;186:784–9PubMedGoogle Scholar
  21. 21.
    Duarte G, Read JS, Gonin R, et al. Mode of delivery and postpartum morbidity in Latin America and Caribbean countries among women who are infected with human immunodeficiency virus-1:The NICHD International Site Development Initiative (NISDI) Perinatal study. Am J Obstet Gynecol. 2006;195:215–29.PubMedGoogle Scholar
  22. 22.
    Louis J, Landon MB, Gersnoviez RJ, et al. Perioperative morbidity and mortality among human immunodeficiency virus-infected women undergoing cesarean delivery. Obstet Gynecol. 2007;110:385–390.PubMedGoogle Scholar
  23. 23.
    Sebitloane HM, Modly J, Esterhuinzen TM. Prophylactic antibiotics for the prevention of postpartum infectious morbidity in women infected with human immunodeficiency virus: a randomized controlled trial. Am J Obstet Gynecol. 2008;198:189–90PubMedGoogle Scholar
  24. 24.
    Menacker F. Trends in Cesarean Rates for First Births and Repeat Cesarean Rates for Low Risk Women, United States, 1990–2003. National Vital Statistics Report, Center for Disease Control and Prevention.Google Scholar
  25. 25.
    Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries, Obstet Gynecol. 2006;107:1226–32.PubMedGoogle Scholar
  26. 26.
    Knight M, Kurinczuk JJ, Spark P, Brocklehurst P. For the United Kingdom Obstetrics Surveillance System Steering Committee. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol. 2008;111:97–105.PubMedGoogle Scholar
  27. 27.
    CDC. Success in implementing PHS guidelines to reduce perinatal transmission of HIV – Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995 and 1996. MMWR 1998;47:688–91.Google Scholar
  28. 28.
    Wiznia AA, Crane M, Lambert G, et al. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban center. JAMA. 1996;275:1504–6.PubMedGoogle Scholar
  29. 29.
    Sambamoorthi U, Akincigil A, McSpiritt E, et al. Zidovudine use during pregnancy among HIV-infected women on Medicaid. J Acquir Immune Defic Syndr. 2002;30(4):429–39.PubMedGoogle Scholar
  30. 30.
    Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-testing during labor: A multicenter study. JAMA. 2004;292:219–23.PubMedGoogle Scholar
  31. 31.
    Jamieson DJ, Cohen MH, Maupin R, et al. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience. Am J Obstet Gynecol. 2007;197(3 Suppl):S72–82.PubMedGoogle Scholar
  32. 32.
    Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistence mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15(15):1951–7.PubMedGoogle Scholar
  33. 33.
    Cunningham CK, Chaix M, Rekaccwicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis. 2002;186:181–8.PubMedGoogle Scholar
  34. 34.
    Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;315(3):229–39.Google Scholar
  35. 35.
    Lockman S, Shapiro RL, Smeaton LM, et al. Response to Antiretroviral Therapy after a single, peripartum Dose of Nevirapine. N Engl J Med 2007;356:135–47.PubMedGoogle Scholar
  36. 36.
    Chaix M, Ekouevi DK, Rouet F, et al. Low Risk of Nevirapine Resistance Mutations in the Prevention of Mother to Child Transmission of HIV: Agence Nationale de Recherches sur le SIDa Ditrame Plus, Abidjan, Cote d'Ivorie. J Infect Dis. 2006;193:482–7.PubMedGoogle Scholar
  37. 37.
    Chi B, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine foe perinatal HIV prevention: an open-label randomized trial. Lancet 2007;370:1698–705.PubMedGoogle Scholar
  38. 38.
    Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12 month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type1, Ivory Coast, 2003–2006. Clin Infect Dis. 2006;46:611–2.Google Scholar
  39. 39.
    for Disease Control and prevention. Enhanced Perinatal Surveillance-United States, 1999–2001. Atlanta: US Department of Health and Human Services, Centers for Disease Control and prevention; 2004:1–22. Special Surveillance Report 4.Google Scholar
  40. 40.
    Steele B, Meléndez-Morales L, Campoluci R, DeLuca N, Dean HD. Health Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis: Issues, Burden, and Response, A Retrospective Review, 2000–2004. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, November 2007. Available at: http://www.cdc.gov/nchhstp/healthdisparities/
  41. 41.
    Donegan SP, Steger KA, Lakambini R, et al. Seroprevalence of human immunodeficiency virus in parturients at Boston City Hospital:Implications for public health and obstetric practice. Am J Obstet Gynecol. 1992;167:622–9.PubMedGoogle Scholar
  42. 42.
    Anderson JE, Ebrahim SH, Sansom S. Women's Knowledge about treatment to prevent mother to child human immunodeficiency virus transmission. Obstet Gynecol. 2004;103:165–8.PubMedGoogle Scholar
  43. 43.
    ACOG Committee Opinion Health Literacy. Number 391, December 2007. Obstet Gynecol. 2007;110(6):1489–91.Google Scholar
  44. 44.
    BB Pharmacokinetics during pregnancy: Evidence-Based maternal dose formulation. Obstet Gynecol. 199;93:858–68.Google Scholar
  45. 45.
    Tracy TS, Venkataramanan R, Glover DD, Caritis SN. For the NICHD Network of MFM units. Temporal changes in drug metabolism (CY1A2, CYP2D6 and CYP 3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633–9.PubMedGoogle Scholar
  46. 46.
    O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected With human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group Study (protocol 082). Am J Obstet Gynecol. May 1993;168 (5):1510–1516.PubMedGoogle Scholar
  47. 47.
    Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol. 2001;184:153–8.PubMedGoogle Scholar
  48. 48.
    Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez A, et al. Pharmacokinetics of Didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: An AIDS Clinical Trials Group Study. JID. 1999;180–1536–41.Google Scholar
  49. 49.
    Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, et al. Pharmacokinetics and safety of stavudine in HIV infected pregnant women and their infants: Pediatrics AIDS Clinical Trials Group Protocol 332. J Infect Dis. 2004;190:2167–74.PubMedGoogle Scholar
  50. 50.
    Brokie BM, Mirochnick M, Caparelli EV, et al. For the PACTG 1026s Study Team. Impact of Pregnancy on Abacavir Pharmacokinetics. AIDS. 20(4):553–460, 2006.Google Scholar
  51. 51.
    Mirochnick M, Fenton T, Gagnier P, et al. for the Pediatric AIDS Clinical Trials Group Protocol 250 Team. Pharmacokinetics of nevirapine in human imunodeficiency virus type 1 infected pregnant women and their neonates. J Infect Dis. 1998;178(2):368–74.PubMedGoogle Scholar
  52. 52.
    Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16(2):299–300.PubMedGoogle Scholar
  53. 53.
    Dear Health Care Provider. Re: Important change in Sustiva (Efavienz) package insert-Change from Pregnancy Category C to D Bristol Myers Squibb Company. March 2005Google Scholar
  54. 54.
    Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007. Wilmington, NC: Registry Coordinating Center; 2007. Available At (http://www.APRegistry.com)
  55. 55.
    Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, et al. Pharmacokinetics of saquinavir SGC in HIV Infected pregnant women. HIV Clinical Trials 2001;2(6):460–5.PubMedGoogle Scholar
  56. 56.
    Stek A, Mirochnick M, Capparelli E, et al. For the Pediatric AIDS Clinical Trials Group (PACTG) 1026 team. Reduced Lopinavir Exposure During Pregnancy. AIDS. 2006;20:1931–9.PubMedGoogle Scholar
  57. 57.
    Bryson Y, Stek A, Mirochnick M, Mofenson L, et al. For the PACTG 353 Team Pharmacokinetics, Antiviral Activity, and Safety of Nelfinavir (NFV) with ZDV/3TC in Pregnant HIV-Infected Women and Their Infants: PACTG 353 Cohort 2. Abstract 795; 9th Conference on Retroviruses and Opportunistic Infections. Boston, US 2003.Google Scholar
  58. 58.
    Nellen JF, Schillevoort I, Ferdinand WN, Bergshoeff AS, Godfried MH, et al. Nelfinavir Plasma Concentrations are low during pregnancy. CID. 2004;39:736–40.Google Scholar
  59. 59.
    Van Heeswijk RP, Khaliq Y, Gallicano KE, Bourbeau M, Seguin I, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum. Clin Pharmacol Ther. 2004;76:588–97.PubMedGoogle Scholar
  60. 60.
    Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS. 2000;14(8):1061–2.PubMedGoogle Scholar
  61. 61.
    Unadkat JD, Wara DW, Hughes MD, Mathias AA, et al. Pharmacokinetics and Safety of Indinavir in Human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51(2):783–6.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21:2409–15.PubMedGoogle Scholar
  63. 63.
    Mirochnick M, Stek A, Capparelli E, Best B, et al. For the PACTG 1026s Protocol Team. Adequate Lopinavir Exposure Achieved with a Higher Dose During the Third Trimester of Pregnancy. Abstract 710; 13th Conference on Retroviruses and Opportunistic Infections. Denver, US 2006.Google Scholar
  64. 64.
    Best B, Stek A, Hu C, et al. High Dose Lopinavir and Standard-Dose Emtricitabine Pharamacokinetics During Pregnancy and Postpartum. Abstract 629; 15th Conference on Retroviruses and Opportunistic Infections. Boston, US 2008.Google Scholar
  65. 65.
    Marzolini C, Rudin C, Decosterd LA, Telenti A, et al. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16:889–893.PubMedGoogle Scholar
  66. 66.
    Bucceri AM. Somigliana E, Matrone R, Uberti-Foppa C, Vigano P, et al. Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: Insights from plasma human immunodefiency virus-1 RNA viral load and CD4 cell count. Am J Obstet Gynecol. 2003;189:545–51.PubMedGoogle Scholar
  67. 67.
    Somigliana E, Bucceri AM, Tibaldi C, Alberico S, et al. Early invasive diagnostic techniques in pregnant women who are infected with HIV: A multicenter cases series. Am J Obstet Gynecol. 2005;193:437–42.PubMedGoogle Scholar
  68. 68.
    Rodman J, Flynn P, Shapiro D, Bardeguez A, et al. For the PACTG 394 Study Team. Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Infants. Abstarct 708; 13th Conference on Retroviruses and Opportunistic Infections. Denver, US 2006.Google Scholar
  69. 69.
    Lo WY, Friedman JM. Teratogenicity of recently introduced medications in Human Pregnancy. Obstet Gynecol. 2002;100:465–73.PubMedGoogle Scholar
  70. 70.
    Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, et al. Prescription use in pregnancy. Am J Obstet Gynecol. 2004;191:398–407.PubMedGoogle Scholar
  71. 71.
    Newschaffer CJ, Cocroft J, Anderson CE, et al. Prenatal zidovudine use and congenital anomalies in a Medicaid population. J Acquir Immune Defic Syndr. 2000;24:249–56.PubMedGoogle Scholar
  72. 72.
    Watts HD, Covington DL, Beckerman K, Garcia P, Scheuerle A, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Ob Obstet Gynecol. 2004;191:985–92.Google Scholar
  73. 73.
    Watts HD, Li D, Handlelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the women and Infants transmission study. J Acquir Immune Defic Syndr. 2007;44(3):299–305.PubMedGoogle Scholar
  74. 74.
    Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy Obstet Gynecol. 2004;103:1181–9Google Scholar
  75. 75.
    Exposure to Antiretroviral Therapy in Utero or Early Life: the Health of Uninfected Children Born to HIV-Infected Women. European Collaborative study. J Acquir Immune Defic Syndr. 2003;32:380–7.Google Scholar
  76. 76.
    Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–9.PubMedGoogle Scholar
  77. 77.
    The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. JAIDS. 2000;25(3):261–268.Google Scholar
  78. 78.
    Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151–7.PubMedGoogle Scholar
  79. 79.
    Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr. 1999;20(5):463–7.Google Scholar
  80. 80.
    Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS. 1998;12: 1805–1813.PubMedGoogle Scholar
  81. 81.
    Bardeguez A, Shapiro D, Mofenson LM, et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal disease progression and survival. J Acquir Immune Defic Syndr. 2003;32:170–81.PubMedGoogle Scholar
  82. 82.
    Watts DH, Lambert JS, Stiehm ER, Harrris R, et al. For the Pediatric AIDS Clinical Trials Group 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr. 2003;33:585–93.PubMedGoogle Scholar
  83. 83.
    Minkoff H, Ahdieh L, Watts H, Greenblatt RM, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. American J Obstet Gynecol. 2001;184:1221–7.Google Scholar
  84. 84.
    Watts DH, Rajalakshmi B, Maupin R, Delke I, et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy:PACTG 316. Am J Obstet Gynecol. 2004;190:506–16.PubMedGoogle Scholar
  85. 85.
    Zorrilla CD, Van Dyke R, Bardeguez A, Acosta E, et al. For the Pediatrics AIDS Clinical Trials Group 386 Protocol Team. Clinical Response, Safety and Tolerability to Saquinavir with Low-dose Ritonavir in HIV-1 Infected Mothers and their Infants. Antimicrob Agents Chemother, 2007;51:2208–2210.PubMedCentralPubMedGoogle Scholar
  86. 86.
    Tuomala RE, Watts H, Li D, et al. Improved obstetrics outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449–73.PubMedGoogle Scholar
  87. 87.
    Bristol-Myers Squibb Company. Healthcare provider important drug warning letter. January 5, 2001.Google Scholar
  88. 88.
    Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous Nevirapine in pregnancy results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772–6.PubMedGoogle Scholar
  89. 89.
    Timmermans S, Templlman C, Godfried MH, et al. Nelfinavir and Nevirapine side effects during pregnancy. AIDS. 2005;19:795–9.PubMedGoogle Scholar
  90. 90.
    Joy S, Poi M, Hughes L, et al. Third trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol. 2005;106:1032–8.PubMedGoogle Scholar
  91. 91.
    Webster Dictionary, 3rd College Edition.Google Scholar
  92. 92.
    Osterberg L, Blaschke T. Adherence to medications. N Eng J Med. 2005;353:487–97.Google Scholar
  93. 93.
    Panel on Antiretroviral Guidelines for adults and Adolescents. Guidelines for the Use of Antitrytroviral Agents in HIV-1 Infected Adult and Adolescents. Department of Health and Human Services. January 29, 2008;1–128. Available at http://www.aidsinfo.nih.gov
  94. 94.
    Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedGoogle Scholar
  95. 95.
    Ross L, Lim ML, Liao Q, et al. Prevalence of antiretrovirak drug resistance and resistance associated mutations in antiretroviral naïve HIV infected individuals from 40 United States cities. HIV Clin Trials. 2007;8:1–8.PubMedGoogle Scholar
  96. 96.
    Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug- resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis. 2001;183:1688–93.PubMedGoogle Scholar
  97. 97.
    Paterson DL, Swindells S, Mohr JA, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMedGoogle Scholar
  98. 98.
    Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13:27–40.PubMedGoogle Scholar
  99. 99.
    Lucas GM, Cheever LW, Chaison RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;71:251–9.Google Scholar
  100. 100.
    Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;3(suppl 3):S136–139.Google Scholar
  101. 101.
    Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Anderson JW, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict non-adherence to antiretroviral therapy in pregnancy: Adherence analysis A5084. AIDS Patient Care STDs. 2008;22(1):29–40.PubMedGoogle Scholar
  102. 102.
    Bardeguez AD, Lindsey JC, Shannon M, Cohn SE, Read JS, Smith E, Ruth ET. Adherence to antiretrovirals (arvs) in U.S. women during and after pregnancy. JAIDS. 2008;48:408–417.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Wilson T, Ickovics JR, Fernandez MI, et al. For the Perinatal Guidelines Evaluation Project. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol. 2001;184(6):1235–40.PubMedGoogle Scholar
  104. 104.
    Ickovics JR, Wilson TE, Royce RA, et al. Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS sub-study from the Perinatal guidelines evaluation project. J Acquir Immune Defic Syndr. 2002;30(3):311–5.PubMedGoogle Scholar
  105. 105.
    van den Broek NR, White SA, Neilson JP. The relationship between asymptomatic human immunodeficiency virus infection and the prevalence and severity of anemia in pregnant Malawian women. Am J Trop Med Hyg. 1998;59:1004–7.PubMedGoogle Scholar
  106. 106.
    Henry DH, Volberding PA, Leitz G. Epoetin alfa for the treatment of anemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;37:1221–7.PubMedGoogle Scholar
  107. 107.
    Sullivan PS, Hanson D, Chu SY, et al. Surveillance for thrombocytopenia in persons infected with HIV: Results from the multistate adult and adolescent spectrum of disease project. J Acquir Immune Defic Syndr. 1997;14:374–9.Google Scholar
  108. 108.
    Miguez-Burbano MJ, Jackson J, Hadrigan S. Thrombocytopenia in HIV Disease: Clinical Relevance, Pathophysiology and Management. Curr Med Chem-cardiovascular & Hematological Agents 2005;3:365–76.Google Scholar
  109. 109.
    Thrombocytopenia in Pregnancy. ACOG Practice Bulletin. Clinical management Guidelines for Obstetrician-Gynecologist. Number 6, September 1999. In ACOG 2008 Compendium of Selected Publications. Volume 2: Practice Bulletins. Pages 581–591.Google Scholar
  110. 110.
    The International Perinatal HIV Group. Duration of rupture membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies. The International Perinatal group. AIDS. 2001;15:357–68.Google Scholar
  111. 111.
    Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus type. Am J Obstet Gynecol. 1995;173:585–9.PubMedGoogle Scholar
  112. 112.
    Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996,34:1617–23.Google Scholar
  113. 113.
    Premature Rupture of Membranes. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician–Gynecologists. Number 80, April 2007. In ACOG 2008 Compendium of Selected Publications. Volume 2: Practice Bulletin. Pages 940–952.Google Scholar
  114. 114.
    Major CA, Towers CV, Lewis DF, Garite TJ. Expectant management of preterm premature rupture of membranes complicated by active recurrent genital herpes. Am J Obstet Gynecol. 2003;188:1551–5.PubMedGoogle Scholar
  115. 115.
    Drake AL, John-Steward GC, Wald A, et al. Herpes Simplex virus type 2 and Risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol. 2007;109:403–9.PubMedGoogle Scholar
  116. 116.
    Alvarez JR, Bardeguez A, Iffy L, Apuzzio J. Preterm premature rupture of membraines in pregnancies complicated by human immunodeficiency virus infection: A single center's five-year experience. J Maternal-Fetal Neonatal Med. 2007;20:853–857.Google Scholar
  117. 117.
    Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal, and neonatal effects. Swiss HIV Cohort Study, The Swiss Collaborative HIV and Pregnancy Study, and The Swiss Neonatal HIV Study. AIDS. 1998;12(18):F241–7.PubMedGoogle Scholar
  118. 118.
    Chamait R, franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV infected pregnant women with impaired glucose tolerance. J Perinatol. 2002;22:370–3.Google Scholar
  119. 119.
    Cotter AM, Gonzalez A, Duthely LM, et al. Ia antiretroviral therapy during pregnancy associated with increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193:1195–201.PubMedGoogle Scholar
  120. 120.
    Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70.PubMedGoogle Scholar
  121. 121.
    Grosch-Woerner I, Puck K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9:6–13.PubMedGoogle Scholar
  122. 122.
    Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm among infants who were born to HIV-infected women duringan era of increased use of maternal antiretrovital drugs:Pediatric Spectrum of HIV disease, 1989–2004. Pediatrics. 2007;119:e900–6.PubMedGoogle Scholar
  123. 123.
    Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: A single center cohort study. JID. 2007;196:558–61.PubMedGoogle Scholar
  124. 124.
    Ravizza M, Martinelli P, Bucceri A, et al. Treatmment with protease inhibitors and co-infection with hepatitis C virus are independent predictors of preterm delivery in HIV-1 infectedpregnant women. JID. 2007;195:913–4.PubMedGoogle Scholar
  125. 125.
    Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviraltherapy in pregnant HIV-infected women and the risk of premature delivery: a meta analysis. AIDS. 2007;21:607–15.PubMedGoogle Scholar
  126. 126.
    Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birthweight and preterm birth. AIDS. 2006;20:2345–53.PubMedGoogle Scholar
  127. 127.
    Beitune PA, Duarte G, Foss M, Montenegro RM, et al. Effect of maternal use of antiretroviral agents on serum insulin levels of the newborn infant. Diabetes Care. 2005;28:856–9.PubMedGoogle Scholar
  128. 128.
    Gestational Diabetes. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 30, September 2001. In ACOG 2008 Compendium of Selected Publications. Volume 2: Practice Bulletin. Pages 695–708.Google Scholar
  129. 129.
    Justman JE, Benning L, Danoff A, Minkoff H, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS. 2003;32:298–302.PubMedGoogle Scholar
  130. 130.
    Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol. 2002;10:187–191.PubMedCentralPubMedGoogle Scholar
  131. 131.
    Hitti J, Anderson J, McComsey G, et al. for the AIDS Clinical Trials Group 5084 Study Team. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007;196:331.e1–331.e7.Google Scholar
  132. 132.
    Watts DH, Balasubraman R, Maupin ET, et al. Maternal Toxicity and pregnancy Complications in HIV-infected women receiving antiretroviral therapy:PACTG 316. Am J Obstet Gynecol. 2004;190:506–16.PubMedGoogle Scholar
  133. 133.
    Hollingsworth DR, Moore TR. Diabetes and Pregnancy Chapter 46: Page 835 in Maternal Fetal Medicine: Principles and Practice. Creasy RK and Resnick R. Editors. 2nd Edition 1989.Google Scholar
  134. 134.
    Brizzi P, Tonolo G, Esposito F, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol. 1999;181:430–4.PubMedGoogle Scholar
  135. 135.
    Fahraeus L, Larsson-Cohn U, Wallentin L, et al. Plasma lipoproteins including high density lipoproteins subfractions during normal pregnancy. Obstet Gynecol. 1985;66:468–72.PubMedGoogle Scholar
  136. 136.
    Livingston E, Cohn SE, Yang Y, et al. For the AIDS Clinical Trials Group A5084 study team. Lipids & Lactate in HIV-1 Infected Pregnancies with/without Protease Inhibitor-Based Therapy. Obstet Gynecol. 2007;110:391–7.PubMedGoogle Scholar
  137. 137.
    DeVore GR, Romero R. Genetic Sonography: An Option for Women of Advanced Maternal Age with Negative Triple-Marker Maternal Serum Screening Results. J Ultrasound in Medicine 2003;22:1191–9.Google Scholar
  138. 138.
    Pinette MG, Egan JFX, Wax JR, et al. Combined Sonographic and Biochemical markers for Down Syndrome Screening. J Ultrasound Med. 2003;22:1185–90.PubMedGoogle Scholar
  139. 139.
    Biggio JR, Morris C, Owen J, Stringer JS. An Outcomes Analysis of Five Prenatal Screening Strategies for Trisomy 21 in Women Younger than 35 years. Am J Obstet Gynecol. 2004;190:721–9.PubMedGoogle Scholar
  140. 140.
    Hobbins JC, Lezotte DC, Persutte WH, et al. An 8-center study to evaluate the utility of midterm genetic sonograms among high risk pregnancies. J Ultrasound Med. 2003;22:33–8.PubMedGoogle Scholar
  141. 141.
    Coll O, Suy A, Hernandez S, et al. Prenatal diagnosis in human immunodeficiency virus-infected women: A new screening program for chromosomal anomalies. Am J Obstet Gynecol. 2006;194:192–8.PubMedGoogle Scholar
  142. 142.
    Shapiro DE, Sperling RS, Mandelbrot L, et al. Risk factors for perinatal human immunodeficiency transmission in patients receiving zidovudine prophylaxis. PACTG Protocol 076 Study Group. Obstet Gynecol. 1999;94:897–908.PubMedGoogle Scholar
  143. 143.
    Gross S, Castillo W, Crane M, et al. Maternal serum alpha fetoprotein and human chorionic gonadotropin levels in women with HIV Am J Obstet Gynecol. 2003;188:1052–6.PubMedGoogle Scholar
  144. 144.
    Yudin MH, Prosen TL, Landers DV. Multiple marker screening in HIV positive pregnant women: Screen positivity rates with the triple and quad screen Am J Obstet Gynecol. 2003:189:973–6.PubMedGoogle Scholar
  145. 145.
    Einstein FH, Wright RL, Trentacoste S, et al. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive Am J Obstet Gynecol. 2004;191:1004–8.PubMedGoogle Scholar
  146. 146.
    Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetrics factors and mother-to-child transmission of human immunodeficiency virus type1: The French perinatal cohorts. Am J Obstet Gynecol. 1996;175:661–7.PubMedGoogle Scholar
  147. 147.
    Bucceri AM, Somigliana E, Vignali M. Early invasive diagnostic techniques during pregnancy in HIV-infected women. Acta Obstet Gynecol Scand. 2001;80:82–83.PubMedGoogle Scholar
  148. 148.
    The European Collaborative Study. Fluctuations in Symptoms in Human Immunodeficiency Virus-Infected Children: The First 10 Years of Life. Pediatrics. 2001;108:116–122.Google Scholar
  149. 149.
    Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–1528.PubMedGoogle Scholar
  150. 150.
    Resino S, Bellon JM, resino R, Navarro L, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children. CID. 2004;38:1605–12.Google Scholar
  151. 151.
    Zorrilla C, Febo I, Ortiz I, et al. Pregnancy in perinatally HIV-infected adolescents and young adults – Puerto Rico, 2002. MMWR Weekly. 2003;52:149–151.Google Scholar
  152. 152.
    Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J of Public Health 2007;97:1047–1052.Google Scholar
  153. 153.
    Fraser AM, Brockert JE, Ward RH. Association of young maternal age with adverse reproductive outcomes. N Engl J Med. 1995;332:1113–7.PubMedGoogle Scholar
  154. 154.
    Jolly MC, Sebire N, Harris J, Robinson S, Regan L. Obstetric Risks of Pregnancy in Women Less than 18 years old. Obstet Gynecol. 2000;96:962–6.PubMedGoogle Scholar
  155. 155.
    Chen XK, Wen SW, Fleming N, Demissie K, Rhoads GG, Walker M. Teenage pregnancy and adverse birth outcomes: a large population based retrospective cohort study. Int J Epidemiol. 2007;36:368–73.PubMedGoogle Scholar
  156. 156.
    Williams S, Keane M, Bettica L, Dieudonne A, Bardeguez A. Adeherence Issues and Viral Suppression in Perinatally-Infected Pregnant Adolescents. Infectious Disease Society for Obstetrics and Gynecology, 34th Annual Scientific Meeting. Boston, Mass, August 9 2007.Google Scholar
  157. 157.
    Williams S, Keane M, Bettica L, Dieudonne A, Bardeguez A: Pregnancy and neonatal outcomes of perinatally-infected HIV adolescents and young adults. International AIDS Society Conference, Sydney, Australia 2007. Abstract Number: TUPEB112.Google Scholar
  158. 158.
    McConnell M, Clark H, Zorrilla C, et al. Pregnancy in Perinatally HIV-infected youth. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24–27, 2005. Abstract number: MoPeLB9.5C01.Google Scholar
  159. 159.
    Sharma A, Feldman JG, Golub ET, et al. Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol. 2007;196:541.e1–541.e6.PubMedCentralGoogle Scholar
  160. 160.
    Hawes SE, Critchlow CW, Faye MA, et al. Increased Risk of high grade cervical squamous intraepithelial lesions and invasive cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis. 2003;188:55–63.Google Scholar
  161. 161.
    Jakobson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2007;109:309–13.Google Scholar
  162. 162.
    Moscicki A, Ellenberg JH, Crowley-Nowick P, et al. Risk of High-grade squamous intraepithelial lesion in HIV infected adolescents. JID. 2004;190:1413–21.PubMedGoogle Scholar
  163. 163.
    Viral Hepatitis in Pregnancy ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 86, October 2007. Obstet Gynecol. 2007;110(4):941–955.Google Scholar
  164. 164.
    Santiago-Munoz P, Scott R, Sheffield J, et al. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2005;193:1270–3.PubMedGoogle Scholar
  165. 165.
    Chen JL, Phillips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect. 2001;33(4):144–152.PubMedGoogle Scholar
  166. 166.
    Bedimo-Rung AL, Clark RA, Dumestre J, Rice J, Kissinger P. Reproductive decision-making among HIV-infected women. J Natl Med Assoc. 2005;97:1403–10.PubMedGoogle Scholar
  167. 167.
    Klein J, Pena JE, Thornton II MH, Sauer MV. Understanding the motivations, concerns and desires of human Immunodeficiency virus 1 serodiscordant couples wishing to have children through assisted reproduction. Obstet Gynecol. 2003;101:987–94.PubMedGoogle Scholar
  168. 168.
    Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predictors on conception. Miscarriage and abortion in US women with HIV. AIDS. 2004;18:281–286.PubMedGoogle Scholar
  169. 169.
    Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004;103:663–8.PubMedGoogle Scholar
  170. 170.
    Goldman-Clery J, Pena JE, Thornton MH, et al. Obstetrics Outcomes of Human Immunodeficiency virus 1 serodiscordant couples following in vitro fertilization with intracytoplasmic sperm injection. Am J Perinatol. 2003;29:305–311.Google Scholar
  171. 171.
    Al-Khan A, Colon J, Palta V, Bardguez A. Assisted reproductive technology for men and women infected with human immunodeficiency virus type 1. CID. 2003;36:195–200.Google Scholar
  172. 172.
    Lyerly AD, Anderson J, Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics. Fertil Steril. 2001;75:843–58.PubMedGoogle Scholar
  173. 173.
    Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, et al. for the Pediatrics AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of Saquinavir plus Low dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant women. Antimicrob Agents Chemother. 2004;48(2):430–6.PubMedCentralPubMedGoogle Scholar
  174. 174.
    ACOG Committee Opinion Prevention of Early – Onset Group B Streptococcal Disease in Newborns. Number 279. December 2002 In ACOG 2008 Compendium of Selected Publications. Volume 1: Committee Opinions and Policy Statements. Pages 425–32.Google Scholar
  175. 175.
    Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr. 2000;25:306–11.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Arlene D. Bardeguez
    • 1
  1. 1.Department of Obstetrics and Gynecology and Women’s HealthUMDNJ-New Jersey Medical SchoolNewarkUSA

Personalised recommendations